

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Termination and Release of Security Interest in Trademarks and Patents at Reel/Frame: 4448/0645

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Oxford Finance Corporation		03/03/2011	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	BioVex Limited
Street Address:	70 Milton Park
Internal Address:	Abingdon
City:	Oxon
State/Country:	UNITED KINGDOM
Postal Code:	OX14 4RX
Entity Type:	Limited Company: UNITED KINGDOM

PROPERTY NUMBERS Total: 5

Property Type	Number	Word Mark
Registration Number:	2638337	BIOVEX
Registration Number:	2661546	NEUROVEX
Registration Number:	2749287	EXPRESSGEN
Registration Number:	2852365	ONCOLYSE
Registration Number:	3032567	ONCOVEX

CORRESPONDENCE DATA

Fax Number: (617)526-5000
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 617-526-6448
 Email: huelinh.tran@wilmerhale.com
 Correspondent Name: Michael J. Bevilacqua, Esq.
 Address Line 1: Wilmer Cutler Pickering Hale and DorrLLP
 Address Line 2: 60 State Street
 Address Line 4: Boston, MASSACHUSETTS 02109

OP \$140.00 2638337

TRADEMARK

900185467

REEL: 004489 FRAME: 0642

ATTORNEY DOCKET NUMBER:	287.572.149
DOMESTIC REPRESENTATIVE	
Name:	Michael J. Bevilacqua, Esq.
Address Line 1:	Wilmer Cutler Pickering Hale and DorrLLP
Address Line 2:	60 State Street
Address Line 4:	Boston, MASSACHUSETTS 02109
NAME OF SUBMITTER:	Michael J. Bevilacqua
Signature:	/michael j. bevilacqua/
Date:	03/03/2011
Total Attachments: 6 source=termination and release of security interest oxford finance to biovex limited#page1.tif source=termination and release of security interest oxford finance to biovex limited#page2.tif source=termination and release of security interest oxford finance to biovex limited#page3.tif source=termination and release of security interest oxford finance to biovex limited#page4.tif source=termination and release of security interest oxford finance to biovex limited#page5.tif source=termination and release of security interest oxford finance to biovex limited#page6.tif	

TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS AND PATENTS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS AND PATENTS (the "Release") is made this 3rd day of March, 2011 (the "Release Date") by Oxford Finance Corporation, a Delaware corporation (in its capacity as collateral agent, the "Collateral Agent") for the Lenders, in favor of BioVex Limited, a limited company registered under the laws of England and Wales ("BioVex").

WHEREAS, BioVex entered that certain Loan and Security Agreement by and among the Lenders, the Collateral Agent, BioVex Inc., a Delaware corporation, and BioVex Group, a Delaware corporation, dated as of December 22, 2010 (the "Loan Agreement"), pursuant to which a security interest was granted in certain collateral, including the Trademark Collateral (as hereinafter defined) and the Patent Collateral (as hereinafter defined);

WHEREAS, pursuant to the Loan Agreement, BioVex entered into that certain Intellectual Property Security Agreement, dated as of December 22, 2010 (as at any time prior to the date hereof amended, supplemented or otherwise modified, the "Security Agreement") with Collateral Agent, for the purpose of recording Collateral Agent's security interest with respect to the Trademark Collateral and the Patent Collateral, including the trademarks set forth on Exhibit A and the patents set forth on Exhibit B, with the United States Patent and Trademark Office (the "USPTO");

WHEREAS, Collateral Agent recorded with the USPTO a notice of security interest in the Trademarks on January 7, 2011, at Reel 4448, Frame 0645;

WHEREAS, Collateral Agent recorded with the USPTO a notice of security interest in the Patents on January 7, 2011, at Reel 025603, Frame 0468;

WHEREAS, BioVex has requested that Collateral Agent release and reassign any interest that Collateral Agent may have in the Trademark Collateral and the Patent Collateral to BioVex, and Collateral Agent has agreed to such release and reassignment; and

WHEREAS, BioVex has notified Collateral Agent that all right, title and interest in and to the Trademark Collateral and the Patent Collateral is owned by BioVex.

NOW THEREFORE, in consideration thereof and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Collateral Agent agrees as follows:

1. Definitions. The term "Trademark Collateral," as used herein shall mean all of BioVex's right, title and interest of every kind and nature as of the date hereof in the Trademarks (including the Trademarks set forth on Exhibit A); the term "Patent Collateral," as used herein shall mean all of BioVex's right, title and interest of every kind and nature as of the date hereof in the Patents (including the Patents set forth on Exhibit B).

2. Release of Security Interest. Effective as of the Release Date, Collateral Agent hereby irrevocably and forever terminates, releases and discharges any and all security interests, and reassigns to BioVex any right, title or interest, it has in the Trademark Collateral and the Patent Collateral as of the date hereof.

3. Recordation of Release. Collateral Agent understands and agrees that this Release may be recorded by or for BioVex with the USPTO.


4. Further Actions. Collateral Agent further agrees to execute any other documents and take any further action reasonably necessary in any state, country or jurisdiction that BioVex may reasonably require to effect the intent and purpose of this Release, provided that all such documents are to be prepared by counsel to BioVex and the cost and expense of such documents and actions shall be borne solely by BioVex.

5. Capitalized Terms. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Security Agreement.

[Signature pages follow]

IN WITNESS WHEREOF, Collateral Agent has caused this Release to be executed as an instrument under seal by its duly authorized officer as of the Release Date.

OXFORD FINANCE CORPORATION,
as Collateral Agent

By: 
Name: John G. Henderson
Title: Vice President & General Counsel

[Signature Page to Termination and Release of Security Interest in Trademarks]

EXHIBIT A

Issued Registrations

<u>Owner of Record</u>	<u>Mark</u>	<u>Reg. No.</u>	<u>Filing Date</u>	<u>Issue date</u>
BioVex Limited	BIOVEX	2,638,337	September 19, 2000	October 22, 2002
BioVex Limited	NEUROVEX	2,661,546	September 19, 2000	December 17, 2002
BioVex Limited	EXPRESSGEN	2,749,287	January 26, 2001	August 12, 2003
BioVex Limited	ONCOLYSE	2,852,365	February 13, 2001	June 15, 2004
BioVex Limited	ONCOVEX	3,032,567	September 19, 2000	December 20, 2005

EXHIBIT B

Patents

- 1 Patent #: 6248320 Issue Dt: 06/19/2001 Application #: 09230479 Filing Dt: 06/10/1999
Title: HSV STRAIN LACKING FUNCTIONAL ICP27 AND ICP34.5 GENES
- 2 Patent #: 6719982 Issue Dt: 04/13/2004 Application #: 09601102 Filing Dt: 02/20/2001
Title: MUTANT HERPES SIMPLEX VIRUSES AND USES THEREOF
- 3 Patent #: 6641817 Issue Dt: 11/04/2003 Application #: 09744942 Filing Dt: 08/06/2001
Title: HERPES VIRUS VECTORS FOR DENDRITIC CELLS
- 4 Patent #: 7262033 Issue Dt: 08/28/2007 Application #: 09762098 Filing Dt: 06/20/2001
Title: CELL LINES FOR THE PROPAGATION OF MUTATED HERPES VIRUSES
- 5 Patent #: 6713067 Issue Dt: 03/30/2004 Application #: 09833073 Filing Dt: 04/12/2001
Publication #: US20020099006 Pub Dt: 07/25/2002
Title: HERPES VIRUSES FOR IMMUNE MODULATION
- 6 Patent #: 6821753 Issue Dt: 11/23/2004 Application #: 10168796 Filing Dt: 09/18/2002
Publication #: US20030082142 Pub Dt: 05/01/2003
Title: REPLICATION INCOMPETENT HERPES VIRUSES FOR USE IN GENE THERAPY
- 7 Patent #: NONE Issue Dt: Application #: 10168801 Filing Dt: 09/11/2002
Publication #: US20030040500 Pub Dt: 02/27/2003
Title: Replication incompetent herpes virus vectors
- 8 Patent #: 7063835 Issue Dt: 06/20/2006 Application #: 10181692 Filing Dt: 11/12/2002
Publication #: US20030113348 Pub Dt: 06/19/2003
Title: VIRUS STRAINS
- 9 Patent #: 7223593 Issue Dt: 05/29/2007 Application #: 10181697 Filing Dt: 10/02/2002
Publication #: US20030091537 Pub Dt: 05/15/2003
Title: HERPES VIRUS STRAINS FOR GENE THERAPY
- 10 Patent #: NONE Issue Dt: Application #: 10181698 Filing Dt: 07/19/2002
Publication #: US20020192802 Pub Dt: 12/19/2002
Title: Replication competent herpes virus strains
- 11 Patent #: 7063851 Issue Dt: 06/20/2006 Application #: 10273348 Filing Dt: 10/18/2002
Publication #: US20040022812 Pub Dt: 02/05/2004
Title: HERPES VIRUSES FOR IMMUNE MODULATION
- 12 Patent #: NONE Issue Dt: Application #: 10355248 Filing Dt: 01/31/2003
Publication #: US20030219409 Pub Dt: 11/27/2003
Title: Eukaryotic gene expression cassette and uses thereof
- 13 Patent #: NONE Issue Dt: Application #: 10668164 Filing Dt: 09/24/2003
Publication #: US20040063094 Pub Dt: 04/01/2004
Title: Mutant herpes simplex viruses and uses thereof

- Patent #: 7118755 Issue Dt: 10/10/2006 Application #: 10766897 Filing Dt: 01/30/2004
14 Publication #: US20040219167 Pub Dt: 11/04/2004
Title: HERPES VIRUSES FOR IMMUNE MODULATION
- Patent #: NONE Issue Dt: Application #: 11155688 Filing Dt: 06/20/2005
15 Publication #: US20050249707 Pub Dt: 11/10/2005
Title: Herpes virus vectors for dendritic cells
- Patent #: 7811582 Issue Dt: 10/12/2010 Application #: 11333309 Filing Dt: 01/18/2006
16 Publication #: US20060121522 Pub Dt: 06/08/2006
Title: HERPES VIRUSES FOR IMMUNE MODULATION
- Patent #: NONE Issue Dt: Application #: 11339804 Filing Dt: 01/25/2006
17 Publication #: US20060188480 Pub Dt: 08/24/2006
Title: VIRAL VECTORS
- Patent #: 7537924 Issue Dt: 05/26/2009 Application #: 11372613 Filing Dt: 03/10/2006
18 Publication #: US20070003571 Pub Dt: 01/04/2007
Title: VIRUS STRAINS
- Patent #: NONE Issue Dt: Application #: 12708692 Filing Dt: 02/19/2010
19 Publication #: US20100143309 Pub Dt: 06/10/2010
Title: VIRAL VECTORS